GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

avelumab   Click here for help

GtoPdb Ligand ID: 8735

Synonyms: Bavencio® | MSB-0010718C | MSB0010718C
Approved drug Immunopharmacology Ligand
avelumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Avelumab is a programmed death-ligand 1 (PD-L1; CD274) blocking human IgG1 lambda monoclonal antibody . It is the first drug approved for the treatment of Merkel cell carcinoma (MCC).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Bioactivity Comments
A patent search identifies that peptide sequences of the heavy and light chains of avelumab are identical to SEQ ID NO: 24 and SEQ ID NO: 25 (respectively) in WO2013079174 A1 [1]. The data in the table below is that proovided for clone A09-246-2, a preferred embodiment of the patent.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 ligand 1 Primary target of this compound Hs Antibody Binding 10.1 pIC50 - 1
⤷ pIC50 10.1 (IC50 7.1x10-11 M) [1]
Description: Measuring inhibition of PD-1 binding to PD-L1.